SCHEMBL4524263

SCHEMBL4524263

Fc1cccc(-c2cscn2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
KMT2A Q03164 1/20 0.53
SCN9A Q15858 1/20 0.51
IDO1 P14902 2/20 0.46
METAP2 P50579 1/20 0.45
METAP1 P53582 1/20 0.45
KMO O15229 2/20 0.44
FYN P06241 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KAT6A Q92794 1/20 0.43
HPGDS O60760 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
MAP4K4 O95819 2/20 0.42
GRM5 P41594 1/20 0.41
F2RL1 P55085 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5322690 0.79 RAB9A (0.54) MEN1MAPTKMT2ASCN9AIDO1
SCHEMBL4518536 0.78 CYP19A1 (0.50) SCN9AIDO1METAP2METAP1KMO
SCHEMBL30989356 0.78 SCN9A (0.51) MEN1KMT2ASCN9AIDO1METAP2
SCHEMBL30042796 0.78 CYP19A1 (0.50) SCN9AIDO1METAP2METAP1KMO
SCHEMBL1879703 0.78 TSHR (0.51) KDM4EMEN1MAPTKMT2ASCN9A
SCHEMBL10151028 0.78 SCN9A (0.51) MEN1KMT2ASCN9AIDO1METAP2
SCHEMBL7389467 0.78 SCN9A (0.48) KDM4EMAPTSCN9AIDO1METAP2
SCHEMBL2789456 0.78 HSD17B1 (0.58) SCN9AMETAP2FYNKAT6A
SCHEMBL1921762 0.77 MGLL (0.50) KDM4ESCN9AALDH1A1KAT6AF2RL1
SCHEMBL22306579 0.76 SCN9A (0.50) MAPTSCN9AMETAP1FYNKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3433234-B1 ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS MERCK SHARP & DOHME (US) 2021-10-27 EP disclosed
CN-109293652-A A kind of substituted thiazole and application thereof 四川科伦博泰生物医药股份有限公司 2019-02-01 CN disclosed
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS HYDRA BIOSCIENCES, INC. 2013-03-07 US disclosed
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 KDM4E 4024/4885MEN1 1785/4885MAPT 2844/4885
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 KDM4E 4704/4885MEN1 3610/4885MAPT 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.